Prevnar 13 Advisory Committee Review Moved Back To November
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.
You may also be interested in...
Prevnar 13 In Older Adults Appears To Have Smooth Path To FDA Approval
Advisory committee to give recommendations on the Pfizer vaccine’s safety and immunogenicity using accelerated approval, but no votes mentioned.
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.